卵巢癌术前新辅助化疗疗效及对组织CA-125、CD_(146)、SP_(70)的表达影响

The effect of preoperative neoadjuvant chemotherapy and expression of CA-125,CD146 and SP70 in ovarian carcinoma

目的:探讨卵巢癌新辅助化疗疗效及组织CA-125、CD_(146)、SP_(70)的表达影响。方法:收集确诊为晚期卵巢癌的患者60例,并同时随机分为两组,试验组与对照组各30例。试验组术前给予新辅助化疗3疗程,然后行常规手术切除治疗,术后再给予化疗3疗程;对照组给予常规手术切除治疗,术后给予同样的化疗方案6疗程,观察两组患者治疗后疗效。同时检测肿瘤组织中的CA-125、CD_(146)、SP_(70)表达水平的改变。结果:试验组的治疗有效率与生存质量均高于对照组,不良治疗预后结局的发生率低于对照组,经检验,差异均有统计学意义(P<0.05)。肿瘤组织中CA-125、CD_(146)、SP_(70)表达稳定;试验组患者组织中CA-125、CD_(146)和SP_(70)表达程度明显低于对照组经检验,差异均有统计学意义(P<0.05)。结论:晚期卵巢癌新辅助化疗联合常规手术治疗具有良好的疗效,并可有效降低肿瘤组织CA-125、CD_(146)、SP_(70)的表达水平;作为近年来逐步肯定的抗体CD_(146)、SP_(70)在肿瘤组织中表达稳定,有望与CA125联合应用成为卵巢癌术后病情监测指标。

Objective： To investigate the effect of neoadjuvant chemotherapy for ovarian cancer and the expression of CA-125, CD146 and SP70. Methods： 60 patients were diagnosed with advanced ovarian cancer after visiting the department of gynecology, and were randomly divided into two groups,the experimental group and control group, with 30 patients in both groups. The experimental group was treated with preoperative neoadjuvant chemotherapy combined with laparoscopic surgery, and the control group was treated with conventional surgical resection. Three times of postoperative chemotherapy were added to observe the curative effect of the two groups after treatment, and the expression levels of CA-125, CD146 and SP70 in tumor tissues were detected. Results： The treatment efficiency and quality of life of the experimental group were higher than in the control group, and the incidence of adverse treatment outcome and the level of CA-125, CD 146 and SP 70 in the tissues of the experimental group were lower than in the control group. Conclusion：Neoadjuvant chemotherapy for advanced ovarian cancer combined with laparoscopic surgery has good efficacy and can effectively reduce the expression levels of CA-125, CD 146 and SP70 in tumor tissues. In recent years, the expression of antibody CD 146 and SP 70 has been gradually confirmed in tumor tissues, which is expected to be used in combination with CA-125 as the indicator of postoperative condition monitoring of ovarian cancer.